Advances in Cancer Immunotherapy for Solid Tumors
Shira Gabizon‐Peretz, Harriet M Kluger · 2026
Read Advances in Cancer Immunotherapy for Solid Tumors by Shira Gabizon‐Peretz, Harriet M Kluger (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13292180.txt.
Description
Shira Gabizon-Peretz and Harriet M Kluger review progress in cancer immunotherapy for solid tumors in a 2026 article. Checkpoint blockers against CTLA-4 and the PD-1 pathway remain the field's backbone. Responses still vary widely, side effects bite, and tumors find escape routes. The review ranges over what is coming next, from new checkpoints to biomarker-guided approvals. Antibody platforms that both target tumors and wake immune cells get special attention.
Adoptive cell therapies, where patients receive engineered immune cells, feature alongside next-generation cytokine drugs. Cancer vaccines aimed at sharpening tumor-specific responses round out the tour. The authors dwell on open problems in resistance biology and in ordering treatments well. Dose and sequence choices can decide whether combinations help or harm. Trial design must keep pace with the platforms, they argue. The overall direction is broader effect with less collateral damage, matched to each patient's tumor.
Catalog record
| CREATOR | Shira Gabizon‐Peretz, Harriet M Kluger |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 115 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |